x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAA-001171
| Product Information | |
|---|---|
| Product Name | Mouse IL-1β ELISA Kit, Fluorescent |
| Species | Mouse |
| Description | IL-1β (Interleukin-1β) in vitro CatchPoint SimpleStep ELISA (Enzyme-Linked Immunosorbent Assay) kit is designed for the quantitative measurement of IL-1β (Interleukin-1β) protein in mouse serum, plasma, urine, cell culture supernatant, and cell and tissue extracts. |
| Sample Types | Cell Culture Supernatant, Urine, Serum, Cell Culture Extracts, Tissue Extracts, Hep Plasma, Edta Plasma, Cit Plasma |
| Detection Range | 0.2 pg/mL - 200 pg/mL |
| Sensitivity | 0.2 pg/mL |
| Target Information | |
|---|---|
| Target Name | IL1B |
| UniProt No. | P01584 |
| Gene ID | 3553 |
| Target Description | Potent proinflammatory cytokine. Initially discovered as the major endogenous pyrogen, induces prostaglandin synthesis, neutrophil influx and activation, T-cell activation and cytokine production, B-cell activation and antibody production, and fibroblast proliferation and collagen production. Promotes Th17 differentiation of T-cells. |
| Alternative Names | Catabolin; H1; IFNβ inducing factor; IL 1; IL 1β; IL-1β; IL1; IL1β; IL1B; IL1B_HUMAN; IL1F2; Interleukin 1β; Interleukin 1β precursor; interleukin 1, β; Interleukin-1β; OAF; Osteoclast activating factor; OTTHUMP00000162031; Preinterleukin 1β; Preinterleukinβ; Pro interleukin 1β |
| Shipping & Storage | |
|---|---|
| Sipping | Shipping on dry ice. |
| Storage | Store at +4°C. Please refer to protocols. |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
